Form 4: Kineta Director Disposes of All Holdings Following TuHURA Biosciences Merger Completion

Kineta, Inc. Director David Arkowitz has reported the disposition of all his common stock and the cancellation of stock options in Kineta following the completion of its merger with TuHURA Biosciences, Inc.

Summary

• David Arkowitz, a Director of Kineta, Inc., reported the disposition of all his beneficial ownership in Kineta common stock and derivative securities on June 30, 2025.
• This disposition occurred pursuant to the Agreement and Plan of Merger, dated December 11, 2024, and amended May 5, 2025, between TuHURA Biosciences, Inc. and Kineta, Inc.
• At the effective time of the merger, each outstanding share of Kineta common stock was cancelled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta common stockholders are also entitled to a pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months post-merger closing, subject to adjustment for losses.
• Additionally, Kineta common stockholders will receive a pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets.
• All Kineta stock options with an exercise price greater than $0.64 per share were canceled and extinguished for no consideration.
• Mr. Arkowitz's 12,500 and 20,000 stock options, both with an exercise price of $3.28, were among those canceled.
• Following the transaction, Mr. Arkowitz holds 0 shares of Kineta Common Stock and 0 derivative securities.

Sentiment

Score: 4

Explanation: The document reports a completed merger, which is a definitive event. However, the cancellation of options for no consideration is a negative for option holders, and the future share issuance is subject to adjustments for losses, introducing some uncertainty for former Kineta shareholders.

Positives

• Completion of a strategic merger, which allows Kineta shareholders to transition their investment into TuHURA Biosciences.
• Kineta shareholders receive TuHURA Common Stock and are eligible for potential future shares and cash consideration from legacy assets.

Negatives

• Kineta stock options with an exercise price greater than $0.64 were canceled for no consideration, resulting in a loss of potential value for option holders, including Mr. Arkowitz.

Risks

• The pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing is subject to adjustment for losses incurred or accrued during that six-month period.

Future Outlook

Kineta common stockholders are entitled to a pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses, and a pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets.

Industry Context

This transaction represents a consolidation within the biotechnology sector, where smaller companies like Kineta are acquired by larger or more strategically aligned entities like TuHURA Biosciences. Such mergers are common for biotech firms seeking to combine pipelines, reduce overhead, or gain access to new capital and expertise.

Comparison to Industry Standards

• The conversion ratio of 0.185298 shares of TuHURA for each Kineta share is specific to this deal and would require detailed financial models of both companies to assess against typical merger premiums or discounts in the biotech sector.
• The contingent issuance of additional shares (1,129,884 TuHURA shares) six months post-merger, subject to loss adjustments, is a common earn-out or contingent value right (CVR) mechanism seen in biotech mergers, designed to align interests and mitigate risks for the acquirer.
• The cancellation of out-of-the-money options (exercise price > $0.64) for no consideration is a standard practice in M&A transactions, particularly when the acquisition price per share is below the option's exercise price, as it prevents dilution from unexercisable options.

Stakeholder Impact

• Shareholders (Kineta): Their Kineta common stock was converted into TuHURA common stock, with potential for additional shares and cash consideration. Those holding options with exercise prices above $0.64 lost their options for no value.
• Employees (Kineta): While not explicitly stated, mergers often lead to organizational restructuring and potential job impacts.
• Management (Kineta): The reporting person, a director, no longer holds Kineta securities, indicating a shift in their relationship with the former entity.

Next Steps

• Issuance of 1,129,884 shares of TuHURA Common Stock to former Kineta stockholders six months following the closing of the Mergers, subject to adjustment for losses.
• Distribution of pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets to former Kineta stockholders.

Key Dates

Keywords

Kineta Inc., TuHURA Biosciences, Merger, SEC Form 4, Stock Disposition, Stock Options, KANT, Biotechnology, Corporate Transaction, Share Exchange